Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- MEDICAL DEVICE NEWS IN BRIEF
September 14, 2009
- 11 New Products, 7 APIs Recommended for NHI Price Listing
September 7, 2009
- Basen Recommended for Approval for Prevention of Type 2 Diabetes
September 7, 2009
- Cervarix Recommended for Approval
September 7, 2009
- REGULATORY NEWS IN BRIEF
September 7, 2009
- Takeda to Initiate Additional Trial for Alogliptin
September 7, 2009
- Astellas to Reshuffle Its Drug Discovery Research Functions
September 7, 2009
- Lilly Drops Arzoxifene Based on Initial PIII Data
September 7, 2009
- R&D NEWS IN BRIEF
September 7, 2009
- 8 APIs Recommended for Switching to OTC Status
September 7, 2009
- Olmetec's Brand Value Ranked No. 1 among ARBs: Nielsen, So-Net M3
September 7, 2009
- Generics Are Not the Same as Original Drugs: Hiroshima Pref. Med. Association
September 7, 2009
- Banyu to Assign 60% of Its MRs for Marketing of Januvia
September 7, 2009
- What Women Want
September 7, 2009
- Pfizer, Astellas to Copromote Caduet
September 7, 2009
- J-TEC Submits Application for JACC
September 7, 2009
- SymBio Will Go Public When Bendamustine Is Approved
September 7, 2009
- Gov't to Rush to Take Measures against New-Type Flu
September 7, 2009
- Price Settlement Rate as of June Shows Improvement to 80.5%
September 7, 2009
- Treatment Recommended in High-Risk Patients Even If Simple Test Result Is Negative
September 7, 2009
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…